<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05793034</url>
  </required_header>
  <id_info>
    <org_study_id>3459</org_study_id>
    <nct_id>NCT05793034</nct_id>
  </id_info>
  <brief_title>Predictive Factors for Survival in Aggressive Meningiomas</brief_title>
  <acronym>23Men</acronym>
  <official_title>Analysis of Predictive Factors for Overall and Progression-free Survival After Neurosurgery for Atypical or Anaplastic Meningioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators plan to collect clinical and molecular data, including ICH, PCR, NGS and&#xD;
      methylome, from patients operated on for grade 2 or grade 3 meningioma. The purpose of the&#xD;
      study is to identify reliable and easy-to-assess predictive factors for recurrence and&#xD;
      survival after surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 7, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence-free survival (RFS)</measure>
    <time_frame>5 years on average</time_frame>
    <description>Correlation from biomolecular data and RFS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>5 years on average</time_frame>
    <description>Correlation from biomolecular data and OS</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Meningioma</condition>
  <condition>Meningioma Atypical</condition>
  <condition>Anaplastic Meningioma</condition>
  <arm_group>
    <arm_group_label>Biological biomarker assessment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>FFPE tumor tissue will be processed with a number of molecular biology techniques</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Biological biomarker assessment</intervention_name>
    <description>IHC, PCR, NGS, methylome</description>
    <arm_group_label>Biological biomarker assessment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient operated for atypical (grade 2) meningioma; or&#xD;
&#xD;
          2. Patient operated for anaplastic (grade 3) meningioma;&#xD;
&#xD;
          3. Timeframe for surgery, 1999-2019&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
        1) Patient lost at follow-up&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alessandro Olivi, MD</last_name>
    <phone>+39 06 3015 4120</phone>
    <email>alessandro.olivi@policlinicogemelli.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rina Di Bonaventura, MD</last_name>
    <phone>+39 06 3015 1</phone>
    <email>rina.dibonaventura@guest.policlinicogemelli.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario A. Gemelli IRCCS</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandro Olivi, MD</last_name>
      <phone>+39 06 3015 4120</phone>
      <email>alessandro.olivi@policlinicogemelli.it</email>
    </contact>
    <contact_backup>
      <last_name>Roberto Pallini, MD, PhD</last_name>
      <phone>+39 06 3015 5414</phone>
      <email>roberto.pallini@unicatt.it</email>
    </contact_backup>
    <investigator>
      <last_name>Rina Di Bonaventura, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Q. Giorgio D'Alessandris, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2023</verification_date>
  <study_first_submitted>February 23, 2023</study_first_submitted>
  <study_first_submitted_qc>March 29, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">March 31, 2023</study_first_posted>
  <last_update_submitted>March 29, 2023</last_update_submitted>
  <last_update_submitted_qc>March 29, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningioma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

